Navigation Links
Enzyme prevents fatal heart condition associated with athletes
Date:5/25/2011

Scientists have discovered an important enzyme molecule that may prevent fatal cardiac disorders associated with cardiac hypertrophy the leading cause of sudden cardiac death in young athletes.

Cardiac hypertrophy is a disease of the heart muscle where a portion of the tissue is thickened without any obvious cause. It is commonly linked to high blood pressure (hypertension) and excessive exercises and results in a shrinking of the heart chamber and a reduction of its blood-pumping volume.

The condition is also associated with fatal cardiac disorders related to irregular heart beats (arrhythmias), leading to millions of deaths worldwide each year, and is perhaps the most well-known cause of sudden cardiac arrest in young sports people.

The researchers used laboratory experiments and computer simulations to show that the enzyme MKK4 is involved in preventing arrhythmias. They believe it does this by modifying another protein, connexion, which forms an electrical bridge between adjacent heart cells to ensure the conduction of electrical activity across the heart as an excitation wave, triggering synchronised mechanical contraction of the heart with a regular heartbeat rhythm.

The multidisciplinary team, writing in The Journal of Biological Chemistry, found that loss of the MKK4 protein disrupts the spatial distribution of connexin, resulting in reduced and non-uniform electrical coupling between heart cells.

This causes a fragmented excitation wave in the heart, leading to uncoordinated heart muscle contraction and irregular heart rhythm. As a result, the heart loses its power to pump blood efficiently, causing disability or sudden cardiac death.

"Using experimental measurements together with detailed computer models, we were able to simulate the electrical activity in cardiac tissue with disrupted electrical coupling between adjacent cardiac cells," said Dr Xin Wang, in Manchester's Faculty of Life Science.

"The information generated from this study will help us to identify whether the MKK4 enzyme could become a therapeutic target for the treatment of cardiac arrhythmias in association with cardiac hypertrophy."

Co-author Professor Henggui Zhang, a biophysicist in Manchester's School of Physics and Astronomy, added: "This research means it would be possible to identify the most important factor behind the sudden cardiac death associated with cardiac hypertrophy, which can affect people of any age with hypertension and also healthy well-trained athletes."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related biology news :

1. UT Southwestern research reveals how cancer-driving enzyme works
2. Nano fit-ness: Helping enzymes stay active and keep in shape
3. Anna-Kaisa Niemi awarded 2011 Genzyme/ American College of Medical Genetics Foundation Fellowship
4. Enzyme can steer cells or possibly stop them in their tracks
5. Production of mustard oils: On the origin of an enzyme
6. Study analyzes role of PARP enzyme in eukaryotes
7. Enzymes from garden compost could favour bioethanol production
8. Enzyme enhances, erases long-term memories in rats
9. DSM and Codexis Sign Enzyme Supply Agreement
10. 1 group of enzymes could have a positive impact on health, from cholesterol to osteoporosis
11. Team looks to the cow rumen for better biofuels enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: